Ramy Huber

Proteomedix AG

Proteomedix enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies. The first product is a blood-based test for the early diagnosis of prostate cancer. The main benefit of this test is a significantly higher accuracy compared to today's clinical standard (blood-based PSA test). This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.